Three December decisions from the Court Of Justice of the European Union shed light on supplementary protection certificates in Europe.
Georgetown University v Octroocentrum Nederland (Netherlands Patent Office)
In 2007, Georgetown University filed eight SPC applications with the Netherlands Patent Office (OCN) based on European patent number 0647140 entitled ‘Papillomavirus vaccine’. The patent was awarded on December 12, 2007 (the day of the SPC application) and expired on June 23, 2013. Two of the SPC applications covered combinations of the active ingredients of the vaccine, four were for the individual active ingredients, and two others related to two of the individual ingredients.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
SPCs, CJEU, supplementary protection certificates, Sanofi, Georgetown